Company Filing History:
Years Active: 2019
Title: Innovations by Guillaume Borrel in Microbial Treatment
Introduction
Guillaume Borrel is an innovative inventor based in Gieres, France. He has made significant contributions to the field of microbiology, particularly in the treatment of conditions related to trimethylamine.
Latest Patents
Guillaume Borrel holds a patent for the use of microorganisms to reduce the level of trimethylamine in human body cavities. This invention is particularly aimed at treating trimethylaminuria and bacterial vaginosis, as well as preventing cardiovascular diseases. The patent describes a composition containing a microorganism, preferably an Archaea, that expresses a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein. This composition is capable of metabolizing trimethylamine in the presence of hydrogen in human cavities, such as the intestine or vagina. The applications of this invention include treating and reducing TMA levels, addressing vaginal fluids in bacterial vaginosis, and minimizing odors caused by TMA. Additionally, it is useful for reducing plasma TMAO levels and preventing the formation of atheroma plaques.
Career Highlights
Guillaume Borrel is affiliated with the Université d'Auvergne Clermont I, where he continues to engage in research and development in microbiology. His work has garnered attention for its potential impact on public health.
Collaborations
Guillaume has collaborated with notable colleagues such as Jean-François Brugere and Paul William O'Toole, contributing to advancements in microbial research.
Conclusion
Guillaume Borrel's innovative work in the use of microorganisms for medical applications highlights the potential of microbiology in addressing significant health issues. His contributions are paving the way for new treatments and preventive measures in healthcare.